The ADCY1 antibody is a crucial tool in biomedical research, targeting adenylate cyclase 1 (ADCY1), a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP). ADCY1 belongs to the adenylate cyclase family, which plays a central role in intracellular signaling by regulating cAMP levels, a secondary messenger involved in diverse physiological processes. Primarily expressed in the brain, particularly in neurons, ADCY1 is implicated in synaptic plasticity, memory formation, and neurotransmitter signaling. It is also found in other tissues, including cardiac and smooth muscle cells, where it modulates cardiovascular functions.
The ADCY1 antibody enables researchers to detect and quantify ADCY1 protein expression, assess its cellular localization, and study its regulatory mechanisms. It is widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate ADCY1's role in health and disease. Dysregulation of ADCY1 has been linked to neurological disorders, such as Alzheimer's disease, and cardiovascular conditions. Additionally, this antibody aids in exploring ADCY1's interaction with G-protein-coupled receptors (GPCRs) and its response to hormonal or pharmacological stimuli.
By facilitating ADCY1-specific research, this antibody contributes to understanding cAMP-mediated pathways and developing targeted therapies for related pathologies. Validation of its specificity and sensitivity ensures reliable experimental outcomes in both basic and translational studies.